The oncology CDMO market is expanding rapidly as rising cancer prevalence fuels demand for specialized outsourcing in drug development and manufacturing. Growing adoption of antibody-drug conjugates, cell and gene therapies, and AI-driven efficiencies is accelerating market growth, with North America leading and Asia Pacific emerging as the fastest-growing region
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Oncology CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Oncology CDMO Market, by Service Type
8.1.1. Process Development & Optimization
8.1.1.1. Market Revenue and Forecast
8.1.2. Active Pharmaceutical Ingredient (API) Manufacturing
8.1.2.1. Market Revenue and Forecast
8.1.3. Drug Product Manufacturing (Formulation & Fill-Finish)
8.1.3.1. Market Revenue and Forecast
8.1.4. Analytical & Quality Testing
8.1.4.1. Market Revenue and Forecast
8.1.5. Packaging & Labeling
8.1.5.1. Market Revenue and Forecast
8.1.6. Regulatory & Compliance Support
8.1.6.1. Market Revenue and Forecast
8.1.7. Cell & Gene Therapy CDMO Services
8.1.7.1. Market Revenue and Forecast
9.1. Oncology CDMO Market, by Drug Type
9.1.1. Small Molecules
9.1.1.1. Market Revenue and Forecast
9.1.2. Biologics
9.1.2.1. Market Revenue and Forecast
9.1.3. Monoclonal Antibodies
9.1.3.1. Market Revenue and Forecast
9.1.4. Antibody-Drug Conjugates (ADCs)
9.1.4.1. Market Revenue and Forecast
9.1.5. Cell & Gene Therapies
9.1.5.1. Market Revenue and Forecast
9.1.6. Vaccines
9.1.6.1. Market Revenue and Forecast
10.1. Oncology CDMO Market, by Phase
10.1.1. Preclinical
10.1.1.1. Market Revenue and Forecast
10.1.2. Clinical (Phase I, II, III)
10.1.2.1. Market Revenue and Forecast
10.1.3. Commercial
10.1.3.1. Market Revenue and Forecast
11.1. Oncology CDMO Market, by End User
11.1.1. Large Pharmaceutical Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Biotechnology Companies
11.1.2.1. Market Revenue and Forecast
11.1.3. Research Institutes
11.1.3.1. Market Revenue and Forecast
12.1. Oncology CDMO Market, by The Oncology Therapy Area
12.1.1. Breast Cancer
12.1.1.1. Market Revenue and Forecast
12.1.2. Lung Cancer
12.1.2.1. Market Revenue and Forecast
12.1.3. Colorectal Cancer
12.1.3.1. Market Revenue and Forecast
12.1.4. Prostate Cancer
12.1.4.1. Market Revenue and Forecast
12.1.5. Leukemia & Lymphoma
12.1.5.1. Market Revenue and Forecast
12.1.6. Solid Tumor Biologics
12.1.6.1. Market Revenue and Forecast
12.1.7. Hematologic Malignancies (Car-T, Cell Therapies) And Targeted ADCs.
12.1.7.1. Market Revenue and Forecast
12.1.8. Others
12.1.8.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Service Type
13.1.2. Market Revenue and Forecast, by Drug Type
13.1.3. Market Revenue and Forecast, by Phase
13.1.4. Market Revenue and Forecast, by End User
13.1.5. Market Revenue and Forecast, by The Oncology Therapy Area
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Service Type
13.1.6.2. Market Revenue and Forecast, by Drug Type
13.1.6.3. Market Revenue and Forecast, by Phase
13.1.6.4. Market Revenue and Forecast, by End User
13.1.6.5. Market Revenue and Forecast, by The Oncology Therapy Area
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Service Type
13.1.7.2. Market Revenue and Forecast, by Drug Type
13.1.7.3. Market Revenue and Forecast, by Phase
13.1.7.4. Market Revenue and Forecast, by End User
13.1.7.5. Market Revenue and Forecast, by The Oncology Therapy Area
13.2. Europe
13.2.1. Market Revenue and Forecast, by Service Type
13.2.2. Market Revenue and Forecast, by Drug Type
13.2.3. Market Revenue and Forecast, by Phase
13.2.4. Market Revenue and Forecast, by End User
13.2.5. Market Revenue and Forecast, by The Oncology Therapy Area
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Service Type
13.2.6.2. Market Revenue and Forecast, by Drug Type
13.2.6.3. Market Revenue and Forecast, by Phase
13.2.7. Market Revenue and Forecast, by End User
13.2.8. Market Revenue and Forecast, by The Oncology Therapy Area
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Service Type
13.2.9.2. Market Revenue and Forecast, by Drug Type
13.2.9.3. Market Revenue and Forecast, by Phase
13.2.10. Market Revenue and Forecast, by End User
13.2.11. Market Revenue and Forecast, by The Oncology Therapy Area
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Service Type
13.2.12.2. Market Revenue and Forecast, by Drug Type
13.2.12.3. Market Revenue and Forecast, by Phase
13.2.12.4. Market Revenue and Forecast, by End User
13.2.13. Market Revenue and Forecast, by The Oncology Therapy Area
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Service Type
13.2.14.2. Market Revenue and Forecast, by Drug Type
13.2.14.3. Market Revenue and Forecast, by Phase
13.2.14.4. Market Revenue and Forecast, by End User
13.2.15. Market Revenue and Forecast, by The Oncology Therapy Area
13.3. APAC
13.3.1. Market Revenue and Forecast, by Service Type
13.3.2. Market Revenue and Forecast, by Drug Type
13.3.3. Market Revenue and Forecast, by Phase
13.3.4. Market Revenue and Forecast, by End User
13.3.5. Market Revenue and Forecast, by The Oncology Therapy Area
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Service Type
13.3.6.2. Market Revenue and Forecast, by Drug Type
13.3.6.3. Market Revenue and Forecast, by Phase
13.3.6.4. Market Revenue and Forecast, by End User
13.3.7. Market Revenue and Forecast, by The Oncology Therapy Area
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Service Type
13.3.8.2. Market Revenue and Forecast, by Drug Type
13.3.8.3. Market Revenue and Forecast, by Phase
13.3.8.4. Market Revenue and Forecast, by End User
13.3.9. Market Revenue and Forecast, by The Oncology Therapy Area
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Service Type
13.3.10.2. Market Revenue and Forecast, by Drug Type
13.3.10.3. Market Revenue and Forecast, by Phase
13.3.10.4. Market Revenue and Forecast, by End User
13.3.10.5. Market Revenue and Forecast, by The Oncology Therapy Area
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Service Type
13.3.11.2. Market Revenue and Forecast, by Drug Type
13.3.11.3. Market Revenue and Forecast, by Phase
13.3.11.4. Market Revenue and Forecast, by End User
13.3.11.5. Market Revenue and Forecast, by The Oncology Therapy Area
13.4. MEA
13.4.1. Market Revenue and Forecast, by Service Type
13.4.2. Market Revenue and Forecast, by Drug Type
13.4.3. Market Revenue and Forecast, by Phase
13.4.4. Market Revenue and Forecast, by End User
13.4.5. Market Revenue and Forecast, by The Oncology Therapy Area
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Service Type
13.4.6.2. Market Revenue and Forecast, by Drug Type
13.4.6.3. Market Revenue and Forecast, by Phase
13.4.6.4. Market Revenue and Forecast, by End User
13.4.7. Market Revenue and Forecast, by The Oncology Therapy Area
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Service Type
13.4.8.2. Market Revenue and Forecast, by Drug Type
13.4.8.3. Market Revenue and Forecast, by Phase
13.4.8.4. Market Revenue and Forecast, by End User
13.4.9. Market Revenue and Forecast, by The Oncology Therapy Area
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Service Type
13.4.10.2. Market Revenue and Forecast, by Drug Type
13.4.10.3. Market Revenue and Forecast, by Phase
13.4.10.4. Market Revenue and Forecast, by End User
13.4.10.5. Market Revenue and Forecast, by The Oncology Therapy Area
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Service Type
13.4.11.2. Market Revenue and Forecast, by Drug Type
13.4.11.3. Market Revenue and Forecast, by Phase
13.4.11.4. Market Revenue and Forecast, by End User
13.4.11.5. Market Revenue and Forecast, by The Oncology Therapy Area
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Service Type
13.5.2. Market Revenue and Forecast, by Drug Type
13.5.3. Market Revenue and Forecast, by Phase
13.5.4. Market Revenue and Forecast, by End User
13.5.5. Market Revenue and Forecast, by The Oncology Therapy Area
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Service Type
13.5.6.2. Market Revenue and Forecast, by Drug Type
13.5.6.3. Market Revenue and Forecast, by Phase
13.5.6.4. Market Revenue and Forecast, by End User
13.5.7. Market Revenue and Forecast, by The Oncology Therapy Area
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Service Type
13.5.8.2. Market Revenue and Forecast, by Drug Type
13.5.8.3. Market Revenue and Forecast, by Phase
13.5.8.4. Market Revenue and Forecast, by End User
13.5.8.5. Market Revenue and Forecast, by The Oncology Therapy Area
14.1. Lonza Group
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Catalent Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. WuXi AppTec
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Samsung Biologics
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Fujifilm Diosynth Biotechnologies
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Thermo Fisher Scientific (Patheon)
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Boehringer Ingelheim BioXcellence
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. AbbVie Contract Manufacturing
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Siegfried Holding AG
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Recipharm AB
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description